Detalhe da pesquisa
1.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
N Engl J Med
; 370(3): 211-21, 2014 Jan 16.
Artigo
Inglês
| MEDLINE | ID: mdl-24428467
2.
Preliminary study of two antiviral agents for hepatitis C genotype 1.
N Engl J Med
; 366(3): 216-24, 2012 Jan 19.
Artigo
Inglês
| MEDLINE | ID: mdl-22256805
3.
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Gastroenterology
; 146(2): 420-9, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24184132
4.
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
J Hepatol
; 60(3): 490-9, 2014 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-24444658
5.
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
Antimicrob Agents Chemother
; 58(6): 3496-503, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24733462
6.
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
Antimicrob Agents Chemother
; 56(7): 3670-81, 2012 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-22508297
7.
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
Antimicrob Agents Chemother
; 56(4): 1838-44, 2012 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22290978
8.
The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Antivir Ther
; 20(1): 29-37, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-24704773
9.
A cell-based model of HCV-negative-strand RNA replication utilizing a chimeric hepatitis C virus/reporter RNA template.
Antivir Chem Chemother
; 13(6): 353-62, 2002 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-12718407
10.
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C.
Clin Pharmacol Drug Dev
; 2(4): 316-27, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-27121936